Frontrunners in race for COVID-19 vaccine
In this file photo taken on November 23, 2020 is pictured a bottle reading "Vaccine Covid-19" next to US pharmaceutical company Pfizer and German biotechnology company BioNTech logos on November 23, 2020. Pharma companies Pfizer and BioNTech on December 1, 2020 filed for European approval for their coronavirus vaccine, following in the footsteps of competitor Moderna, while the OECD predicted the world economy would bounce back to pre-pandemic levels by late 2021.
AFP/Joel Saget

Frontrunners in race for COVID-19 vaccine

(Agence France-Presse) - December 2, 2020 - 8:27pm

PARIS, France — Dozens of companies, from biotech start-ups to Big Pharma, are in the race to develop a safe and effective coronavirus vaccine, both to meet urgent medical need and for the potential payday.

A US-German collaboration between Pfizer and BioNTech surged past a key milestone on Wednesday with Britain's announcement that it would begin rolling out its vaccine — the first Western country to give the green light to an immunisation drive against the coronavirus. 

Its drug is one of several candidate vaccines that have shown promising results in final stage clinical trials, raising hopes the pandemic that has already killed nearly 1.5 million people worldwide can be tamed.

How many in the pipeline?

The World Health Organization (WHO) has identified 49 "candidate vaccines" at the stage of clinical trials in humans by mid-November, up from 11 in mid-June.

Thirteen of them are at the most advanced "Phase 3" stage, in which a vaccine's effectiveness is tested on a large scale, generally on tens of thousands of people across several continents.

Two frontrunner vaccines — by Moderna and BioNTech/Pfizer — have already sought emergency use approval on both sides of the Atlantic.

Pfizer and BioNTech have reported that phase 3 trials for their mRNA vaccine showed 95 percent efficacy in preventing COVID-19 symptoms and did not produce adverse side effects among thousands of volunteers.

Britain said on Wednesday that its National Health Service will begin with 800,000 doses "early next week" and ramp up to "millions" of inoculations by the end of the year. 

BioNTech/Pfizer, which said they expect further regulatory decisions for other countries in the "coming days and weeks", expect to roll out 1.3 billion doses by the end of next year.

US biotech firm Moderna has also said its vaccine showed almost 95 percent efficacy.

The company is on track to manufacture between 500 million to a billion doses globally in 2021, it said.

Results from a European project led by the University of Oxford and AstraZeneca were more complicated. 

Across two variants in the trials with slightly different protocols, the two-dose vaccine worked 70 percent of the time.

But in a part of the trial process that came about by mistake, a group whose first jab was a half-dose rather than a full one showed an efficacy rate of 90 percent. 

In terms of logistics AstraZeneca has an advantage because its candidate can be stored at the temperature of a normal fridge. 

Moderna's vaccine on the other hand must be kept at -20 degrees Celsius, while Pfizer's requires an even chillier -70C to remain viable. 

Russia, which registered two COVID-19 vaccines before trials finished, has said that its Sputnik V vaccine is 95 percent effective according to preliminary data and can be stored in an ordinary fridge. 

The country has started a mass vaccination programme of its military personnel.

Meanwhile, several state-run Chinese labs are also thought to have produced some of the more promising candidate vaccines.

China has been giving experimental COVID-19 vaccines to people including state employees and essential workers heading abroad since July.

The United States and Europe this week fleshed out plans to administer COVID-19 vaccines as soon as they gain approval, expected in the coming weeks.

What kind of vaccines?

Some methods for making a vaccine are tried-and-tested, while others remain experimental.

Inactivated traditional vaccines use a virus germ that has been killed, while others use a weakened or "attenuated" strain.

These vaccines work when the body treats the deactivated pathogen as if it were a real threat, producing antibodies to kill it without endangering the patient with full infection.

So-called "sub-unit" vaccines contain a fragment of the virus or bacteria they are derived from to produce a similar immune response.

"Viral vector" varieties deliver fragments of viral DNA into cells, often hitching a lift from other virus molecules.

For example, a measles virus modified with a coronavirus protein — the apparatus SARS-CoV-2 uses to latch on to human cells — can by deployed to provide immunity to Covid-19. 

Both Pfizer's and Moderna's vaccines are based on cutting-edge technology that uses synthetic versions of molecules called messenger RNA to hack into human cells, and effectively turn them into vaccine-making factories.

Safety first

Trials of two candidate vaccines — made by Johnson & Johnson and Eli Lilly — were "paused" in October over safety concerns.

But that was not necessarily bad news, Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine said at the time.

"The fact that trials are paused should indicate that there should be confidence that the whole process of monitoring the safety of trial participants is working well," he said.

Cases in which recovered Covid patients were infected a second time with a new strain also raise the question of how long vaccines' protection might last.

In October, the US FDA said it would need to see two months of follow-up data after vaccination before giving emergency authorisation for any vaccine use.  

"What is different for COVID-19 vaccines is that speed of development and potential approval is much faster due to the public health emergency," noted the European Medicines Agency (EMA).

But even that pressing need cannot overcome the rules.

"Before approval, all vaccines in the European Union are evaluated against the same high standards as any other medicine," the EMA said in a statement.

As It Happens
LATEST UPDATE: May 11, 2021 - 9:57am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

May 11, 2021 - 9:57am

The US Food and Drug Administration (FDA) on Monday authorized the use of the Pfizer-BioNTech Covid-19 vaccine for children aged 12 to 15 years old.

"This is a promising development in our fight against the virus," said President Joe Biden.

"If you are a parent who wants to protect your child, or a teenager who is interested in getting vaccinated, today's decision is a step closer to that goal."

The FDA previously granted an emergency use authorization for the Pfizer-BioNTech vaccine to individuals aged 16 and older. — AFP

May 10, 2021 - 8:01pm

German firm BioNTech says Monday that the Covid-19 vaccine it developed with Pfizer does not require any modifications at the moment to protect against variants of the virus.

"To date, there is no evidence that an adaptation of BioNTech's current Covid-19 vaccine against key identified emerging variants is necessary," the company says in a statement.

Nevertheless, in preparations for a need at some point to make tweaks to its current vaccine, the company says it began tests in March on a "modified, variant-specific version" of its jabs. —  AFP

May 8, 2021 - 6:23pm

The EU has concluded a deal with BioNTech/Pfizer for up to 1.8 billion extra doses of its COVID-19 vaccine, European Commission chief Ursula von der Leyen says on Saturday.

"Happy to announce that the EU Commission has just approved a contract for guaranteed 900 million doses (+900 million options) with BioNTech/Pfizer for 2021-2023," she tweets from an EU summit in Portugal.

"Other contracts and other vaccine technologies will follow," she promises. — AFP

May 8, 2021 - 5:32pm

Pope Francis offers his support Saturday for waiving coronavirus vaccine patents to boost supply to poorer countries, in a video message to the "Vax Live" concert.

The Argentine pontiff backs "universal access to the vaccine and the temporary suspension of intellectual property rights" in the recording made in his native Spanish.

Francis, who has repeatedly spoken of the need to share vaccines, condemns the "virus of individualism" that "makes us indifferent to the suffering of others." — AFP

May 6, 2021 - 9:00pm

Russian President Vladimir Putin on Thursday said he supported the idea of a waiver on patent protections for coronavirus vaccines and urged his government to consider lifting them for Russia's jabs.

A campaign to lift patent protections on Covid-19 vaccines picked up steam on Thursday, with French, German and EU leadership saying they were ready to discuss a proposal by US President Joe Biden before Putin added his voice in support.

"We are hearing from Europe an idea that, in my opinion, deserves attention -- namely, to remove patent protections from vaccines against COVID-19 altogether," Putin said during a televised meeting with Deputy Prime Minister Tatiana Golikova.

"Russia would of course support such an approach," Putin said, urging Golikova to work out the logistics.

"As I have said many times... We should not think about how to extract maximum profit, but about how to ensure people's safety."  — AFP

  • Latest
Are you sure you want to log out?

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

or sign in with